This project aims to provide an exhaustive analysis of how pharmaceutical mergers and acquisitions affect market competition and prices of patent-protected branded drugs involved in the deal. So far, little direct evidence exists about the impact of mergers and acquisitions activity on pharmaceutical market outcomes, partly because reliable data on prices and ownership of drugs is very difficult to obtain. The scholars will assemble a comprehensive dataset tracking the ownership of new products. This will be one of the major contributions of this project since there are no data sources that systematically track the marketing rights of each pharmaceutical product. The project examines whether prices, sales, and formulary coverage of acquired products increase after acquisition and, if so, what types of acquisitions are more likely to lead to changes in these market outcomes. This project will be the first to examine the differences in how list and net prices of pharmaceuticals respond to changes in market structure and competition. It also asks why market outcomes change. Economic theory predicts that within-market (substitute products) mergers will lead to higher prices. More recent evidence suggests that cross-market (noncompeting products) mergers also may generate upward pricing pressure in markets. The project tests these theories in the context of the pharmaceutical market. It also explores alternative explanations, such as shifts in marketing strategy, by incorporating advertising data into the analysis. Finally, the project also investigates anticompetitive effects of acquisitions in the patent-protected branded drugs market and what types of deals are more likely to have an anticompetitive effect.

This project is looking at the effects of “infant acquisitions,” or firms acquiring startups, on the incentives for startups to innovate, and the amount of overall innovation in the technology sector. It will empirically study the impact of megafirms’ tech acquisitions on venture investment by calculating the number of ventures funded and total dollars raised, and patent activities. The effect of large incumbents' acquisitions of startups on innovation has been a major concern among policymakers partly because it may have a negative effect on future investment in venture capital and innovation. Restrictions on tech mergers and acquisitions have been proposed in Europe and in the United States, yet there is still no clear evidence on how they affect venture capital investment. The project will combine three data sources: S&P Global Market Intelligence on firm taxonomy; Crunchbase data on investment deals in tech ventures; and PatentViews open-source data on patents. The combined data sources allow the researchers to paint a fuller picture of each firm’s relative position in the business and technology spaces.

This project aims to provide a detailed, comprehensive analysis of the Amazon.com Inc. platform, its evolution, market power, and welfare implications. Gutierrez will utilize a massive dataset that has product information, alongside prices and sales ranks, for products sold on Amazon’s platform to produce three papers. The first will provide an overview of the Amazon platform and study the evolution and heterogeneity of fees in order to empirically test whether Amazon’s fees to sellers reflect market power. The second will consist of a structural analysis of reselling to test whether Amazon competing on its own platform is anticompetitive. And the third paper will analyze the impact of private label products. This research not only examines the Amazon platform but also provides empirical evidence on whether these types of activities can be anticompetitive.

This project seeks to answer two questions: What are the welfare effects of third-degree price discrimination, and what are the effects of third-degree price discrimination on the take-up of newer and better technologies? Goel will address this question in the context of a particular type of implantable medical device: defibrillators. The implantable medical device industry has three features that make it a compelling setting to study. First, manufacturers are able to prevent hospitals from disclosing prices, allowing them to charge different prices for the same device in different hospitals. Second, the industry is very concentrated, with more than 95 percent of the market share captured by just four firms. And third, there is a lot of product variety. On average, a manufacturer offers six brands of this particular device per year from 2014–2019. Goel will utilize a rich dataset with purchase volumes, prices, and characteristics of defibrillators, and will combine this with approval information from the U.S. Food and Drug Administration. She will then estimate a model of supply and demand, and conduct a counterfactual analysis in which third-degree price discrimination is banned in order to understand the dynamics of price discrimination.

In virtually all areas of the U.S. healthcare service sector, physicians are barred from referring patients to entities in which they have an ownership stake. But this is not the case for the dialysis industry, which is exempt from such restrictions. Joint ventures between physicians and dialysis facilities exist at nearly 20 percent of facilities. This research will explore how physicians’ ownership ties with dialysis firms affect steering, spending, and outcomes. Using data obtained from a Freedom of Information Act request from the Centers for Medicare and Medicaid Services, Eliason, McDevitt, and Roberts will construct a first-of-its-kind dataset that tracks the ownership of dialysis facilities, including whether physicians have an ownership stake. They will add in data on dialysis providers and patients, including detailed Medicare claims and rich information on patient characteristics and health outcomes. An event-study analysis will allow the three researchers to test whether there is a clear trend-break in new patient arrivals and referrals when parties enter into a joint venture in order to examine how integration affects competition. The analysis will enable the researchers to study how patient caseloads and referrals at unintegrated facilities change after a nearby rival forms a joint venture, along with the impact of vertical integration on patient outcomes such as hospitalizations and mortality, as well as overall Medicare spending. Prior research has found that Black, Latinx, and low-income patients suffer disproportionately from kidney failure and often receive worse care, potentially making these groups especially vulnerable to providers’ growing market power and physicians’ conflicting interests.

Jorring and Buchak propose to study the impact of local concentration of mortgage lenders on household credit access and homeownership. Homeownership is the primary channel through which most U.S. households build wealth. Existing literature finds little to no relationship between local lender concentration and mortgage interest rates. Therefore, federal regulators regard mortgage markets as national and view their local concentration as irrelevant to financial regulation and monetary policy. The two researchers argue that this view is incomplete, showing that although local concentration has no influence on interest rates, it strongly affects lending standards and upfront fees. In more concentrated areas, preliminary results show that lenders charge higher fees, mortgage application rejection rates are higher, and the pool of originated mortgages is less risky in terms of both credit scores and default. This may be particularly true for low-income, female, and applicants of color, suggesting that local lender concentration is particularly important when it comes to questions of credit access for traditionally underserved borrowers. Jorring and Buchak plan to combine public data from the Home Mortgage Disclosure Act, which covers the near universe of U.S. mortgage applications, as well as data from Fannie Mae and Freddie Mac on single-family loan origination and performance, with private data to explore the effects of local concentration in mortgage lending.